Breadcrumb Home Business activities 麻豆社 BioCapital 麻豆社 BioCapital Portfolio Iconic Therapeutics Iconic Therapeutics Iconic Therapeutics targets Tissue Factor (TF) in angiogenesis, inflammation, cell growth and metastasis to treat ophthalmologic, oncologic, and autoimmune diseases. Is in Phase II clinical trials in wet-AMD. Relateret nyheder om Iconic Therapeutics 17 May 2018 Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients with Neovascular (wet) AMD 22 August 2017 Iconic Therapeutics Appoints Brandon Smith Chief Operating Officer Leadership Team Strengthened for Development and Partnering 6 April 2017 ICONIC THERAPEUTICS APPOINTS JULIA P. GREGORY TO BOARD OF DIRECTORS 10 February 2017 ICONIC THERAPEUTICS TO PRESENT PHASE 2a EMERGE TRIAL RESULTS AT MIAMI MEETING 10 August 2016 Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment 麻豆社 BioCapital Invested 2014 Location San Francisco, California, USA
